NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced a collaboration with Mayo Clinic supporting a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive and difficult-to-treat childhood brain cancers. The program is supported by a grant recently awarded by the Children's Cancer Research Fund (CCRF) to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research project seeks to address one of the fundamental challenges in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) enables drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit may be limited by the rapid clearance of drugs from the treatment site. The Mayo Clinic team will evaluate a novel combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure following localized drug delivery. The project will begin with large animal studies, and if successful, may expand to human studies in the future.
The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach is designed to enable targeted therapy while providing real-time physiologic monitoring throughout treatment, offering investigators additional insight into both drug delivery and the effects on the surrounding neural environment.
The CCRF award represents an important milestone in advancing this innovative therapeutic approach toward investigational clinical evaluation. The collaboration further expands NeuroOne's growing portfolio of drug delivery initiatives and reflects increasing interest from leading academic investigators and biopharmaceutical companies in the Company's drug delivery platform.
"This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform," said David Wambeke, Chief Business Officer of NeuroOne. "We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording. We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors."
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. For more information, visit nmtc1.com.
